-transparent.png){kind=logo}
D-Met2, Pro5-enkephalinamide (DMPEA) is an opioid peptide having analgesic activity in animals more potent after intravenous administration than morphine. It is less toxic but in animals it showed a higher dependence capacity than morphine. Besides analgesia DMPEA produces in rodent behavioral symptoms similar to those evoked by morphine or beta-endorphin, resembling the actions of neuroleptica. In human trials DMPEA was found to produce unpleasant sensations, no euphoria, and sometimes even dysphoria. DMPEA increases the serum levels of prolactin, growth hormone and, to a less extent, of TSH. Those effect of DMPEA on pituitary hormones. Finally, the human studies indicated that DMPEA antagonized pain (measured with the submaximum effort tourniquet technique), but did not affect adversely and even improved attention and short-term memory; it had no effect on the long-term memory. As the subjective effects of DMPEA are not pleasant, and no patient desired to obtain another treatment, some optimism as to low habit-forming properties of DMPEA may be justified.
J I Székely, and
Z Dunai-Kovács, and
E Miglécz, and
K Polgár, and
K Török, and
J Földes, and
A Váradi, and
C Bános, and
I Karczag, and
J Tolna
November 1982,
Archives internationales de pharmacodynamie et de therapie,
J I Székely, and
Z Dunai-Kovács, and
E Miglécz, and
K Polgár, and
K Török, and
J Földes, and
A Váradi, and
C Bános, and
I Karczag, and
J Tolna
January 1983,
Life sciences,
J I Székely, and
Z Dunai-Kovács, and
E Miglécz, and
K Polgár, and
K Török, and
J Földes, and
A Váradi, and
C Bános, and
I Karczag, and
J Tolna
January 1990,
Acta physiologica Hungarica,
J I Székely, and
Z Dunai-Kovács, and
E Miglécz, and
K Polgár, and
K Török, and
J Földes, and
A Váradi, and
C Bános, and
I Karczag, and
J Tolna
October 1983,
Neuropeptides,
J I Székely, and
Z Dunai-Kovács, and
E Miglécz, and
K Polgár, and
K Török, and
J Földes, and
A Váradi, and
C Bános, and
I Karczag, and
J Tolna
January 1985,
Neuropharmacology,
J I Székely, and
Z Dunai-Kovács, and
E Miglécz, and
K Polgár, and
K Török, and
J Földes, and
A Váradi, and
C Bános, and
I Karczag, and
J Tolna
August 1981,
The Journal of pharmacy and pharmacology,
J I Székely, and
Z Dunai-Kovács, and
E Miglécz, and
K Polgár, and
K Török, and
J Földes, and
A Váradi, and
C Bános, and
I Karczag, and
J Tolna
August 1997,
Drug design and discovery,
J I Székely, and
Z Dunai-Kovács, and
E Miglécz, and
K Polgár, and
K Török, and
J Földes, and
A Váradi, and
C Bános, and
I Karczag, and
J Tolna
April 1985,
European journal of pharmacology,
J I Székely, and
Z Dunai-Kovács, and
E Miglécz, and
K Polgár, and
K Török, and
J Földes, and
A Váradi, and
C Bános, and
I Karczag, and
J Tolna
June 1982,
European journal of pharmacology,
J I Székely, and
Z Dunai-Kovács, and
E Miglécz, and
K Polgár, and
K Török, and
J Földes, and
A Váradi, and
C Bános, and
I Karczag, and
J Tolna
January 1980,
Psychopharmacology,
